Evaluation of the Pharmacokinetics of Trazpiroben (TAK-906), a Peripherally Selective D2/D3 Dopamine Receptor Antagonist, in the Presence and Absence of Itraconazole, a Potent CYP 3A4 Inhibitor

Evaluation of the Pharmacokinetics of Trazpiroben (TAK-906), a Peripherally Selective D2/D3 Dopamine Receptor Antagonist, in the Presence and Absence of Itraconazole, a Potent CYP 3A4 Inhibitor

Chunlin Chen,1 Wenwen Zhang,1 Muhammad Bari,2 Cristina Almansa,1 Mike Baratta,1 Maria Rosario1 1Takeda Development Center Americas, Inc, Cambridge, MA, USA; 2Takeda International UK, Ltd, High Wycombe, UKCorrespondence: Chunlin Chen Email chen_chunlin@hotmail.comPurpose: Treatment options for gastro...

Full description

Bibliographic Details
Main Authors: Chen C, Zhang W, Bari M, Almansa C, Baratta M, Rosario M
Format: Article
Language:English
Published: Dove Medical Press 2021-07-01
Series:Clinical Pharmacology : Advances and Applications
Subjects:
drug–drug interactions
d2/d3 dopamine receptor antagonist
gastroparesis
pharmacokinetics
qt effects
Online Access:https://www.dovepress.com/evaluation-of-the-pharmacokinetics-of-trazpiroben-tak-906-a-peripheral-peer-reviewed-fulltext-article-CPAA

Internet

https://www.dovepress.com/evaluation-of-the-pharmacokinetics-of-trazpiroben-tak-906-a-peripheral-peer-reviewed-fulltext-article-CPAA

Similar Items